Classification of inflammatory skin diseases: A proposal based on the disorders of the three-layered defense systems, barrier, innate immunity and acquired immunity

Journal of Dermatological Science

Volumn 76, Issue 2, 2014, Pages 81-89

  Dainichi, Teruki ^a   Hanakawa, Sho ^a   Kabashima, Kenji ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Acquired immunity; Barrier; Dermatitis; Innate immunity

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT; PROSTANOID; PROTEINASE; PROTEINASE INHIBITOR; REACTIVE OXYGEN METABOLITE;

ACNE; ADAPTIVE IMMUNITY; ATOPIC DERMATITIS; AUTOIMMUNE DISEASE; AUTOIMMUNITY; AUTOINFLAMMATORY DISEASE; DERMATITIS; DISEASE CLASSIFICATION; GENE MUTATION; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PSORIASIS; PYODERMA; REVIEW; ROSACEA; SKIN ALLERGY; SKIN PERMEABILITY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TISSUE SPECIFICITY;

EID: 84908042191     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2014.08.010     Document Type: Review

References (81)

1. Turvey S.E., Broide D.H. Innate immunity. J Allergy Clin Immunol 2010, 125:S24-S32.
2. Kirkpatrick C.H. Chronic mucocutaneous candidiasis. Pediatr Infect Dis J 2001, 20:197-206.
3. Palm N.W., Rosenstein R.K., Medzhitov R. Allergic host defences. Nature 2012, 484:465-472.
4. Cohen P.L., Eisenberg R.A. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 1991, 9:243-269.
5. Anderson M.S., Venanzi E.S., Klein L., Chen Z., Berzins S.P., Turley S.J., et al. Projection of an immunological self shadow within the thymus by the aire protein. Science 2002, 298:1395-1401.
6. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
7. Qian Y., Jeong J.S., Maldonado M., Valenzuela J.G., Gomes R., Teixeira C., et al. Cutting edge: Brazilian pemphigus foliaceus anti-desmoglein 1 autoantibodies cross-react with sand fly salivary LJM11 antigen. J Immunol 2012, 189:1535-1539.
8. Schumann H., Baetge J., Tasanen K., Wojnarowska F., Schacke H., Zillikens D., et al. The shed ectodomain of collagen XVII/BP180 is targeted by autoantibodies in different blistering skin diseases. Am J Pathol 2000, 156:685-695.
9. Roh J.Y., Yee C., Lazarova Z., Hall R.P., Yancey K.B. The 120-kDa soluble ectodomain of type XVII collagen is recognized by autoantibodies in patients with pemphigoid and linear IgA dermatosis. Br J Dermatol 2000, 143:104-111.
10. Tran M., Rousselle P., Nokelainen P., Tallapragada S., Nguyen N.T., Fincher E.F., et al. Targeting a tumor-specific laminin domain critical for human carcinogenesis. Cancer Res 2008, 68:2885-2894.
11. Dainichi T., Kurono S., Ohyama B., Ishii N., Sanzen N., Hayashi M., et al. Anti-laminin gamma-1 pemphigoid. Proc Natl Acad Sci U S A 2009, 106:2800-2805.
12. Honda K., Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 2006, 6:644-658.
13. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
14. Negishi H., Yanai H., Nakajima A., Koshiba R., Atarashi K., Matsuda A., et al. Cross-interference of RLR and TLR signaling pathways modulates antibacterial T cell responses. Nat Immunol 2012, 13:659-666.
15. Marodi L., Notarangelo L.D. Immunological and genetic bases of new primary immunodeficiencies. Nat Rev Immunol 2007, 7:851-861.
16. Netea M.G., Wijmenga C., O'Neill L.A. Genetic variation in Toll-like receptors and disease susceptibility. Nat Immunol 2012, 13:535-542.
17. Minegishi Y., Saito M. Cutaneous manifestations of hyper IgE syndrome. Allergol Int 2012, 61:191-196.
18. Soehnlein O., Lindbom L. Phagocyte partnership during the onset and resolution of inflammation. Nat Rev Immunol 2010, 10:427-439.
19. Markiewski M.M., Lambris J.D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007, 171:715-727.
20. McDermott M.F., Aksentijevich I., Galon J., McDermott E.M., Ogunkolade B.W., Centola M., et al. Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999, 97:133-144.
21. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009, 27:519-550.
22. Gabay C., Lamacchia C., Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010, 6:232-241.
23. Dinarello C.A., Simon A., van der Meer J.W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012, 11:633-652.
24. Masters S.L., Simon A., Aksentijevich I., Kastner D.L. Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu Rev Immunol 2009, 27:621-668.
25. Gul A. Behcet's disease as an autoinflammatory disorder. Curr Drug Targets Inflamm Allergy 2005, 4:81-83.
26. Pineton de Chambrun M., Wechsler B., Geri G., Cacoub P., Saadoun D. New insights into the pathogenesis of Behcet's disease. Autoimmun Rev 2012, 11:687-698.
27. Xiang Q., Chen L., Hou S., Fang J., Zhou Y., Bai L., et al. TRAF5 and TRAF3IP2 gene polymorphisms are associated with Behcet's disease and Vogt-Koyanagi-Harada syndrome: a case-control study. PLoS ONE 2014, 9:e84214.
28. Remmers E.F., Cosan F., Kirino Y., Ombrello M.J., Abaci N., Satorius C., et al. Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behcet's disease. Nat Genet 2010, 42:698-702.
29. Mizuki N., Meguro A., Ota M., Ohno S., Shiota T., Kawagoe T., et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behcet's disease susceptibility loci. Nat Genet 2010, 42:703-706.
30. Brooklyn T.N., Dunnill M.G., Shetty A., Bowden J.J., Williams J.D., Griffiths C.E., et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut 2006, 55:505-509.
31. Jeremy A.H., Holland D.B., Roberts S.G., Thomson K.F., Cunliffe W.J. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003, 121:20-27.
32. Guy R., Green M.R., Kealey T. Modeling acne in vitro. J Invest Dermatol 1996, 106:176-182.
33. Sanders D.A., Philpott M.P., Nicolle F.V., Kealey T. The isolation and maintenance of the human pilosebaceous unit. Br J Dermatol 1994, 131:166-176.
34. Kim J., Ochoa M.T., Krutzik S.R., Takeuchi O., Uematsu S., Legaspi A.J., et al. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002, 169:1535-1541.
35. Pink A.E., Simpson M.A., Desai N., Trembath R.C., Barker J.N. gamma-Secretase mutations in hidradenitis suppurativa: new insights into disease pathogenesis. J Invest Dermatol 2013, 133:601-607.
36. Steinhoff M., Schauber J., Leyden J.J. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol 2013, 69:S15-S26.
37. Lande R., Ganguly D., Facchinetti V., Frasca L., Conrad C., Gregorio J., et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra19.
38. Garcia-Romo G.S., Caielli S., Vega B., Connolly J., Allantaz F., Xu Z., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra20.
39. Bosch X. Systemic lupus erythematosus and the neutrophil. N Engl J Med 2011, 365:758-760.
40. Assassi S., Mayes M.D., Arnett F.C., Gourh P., Agarwal S.K., McNearney T.A., et al. Systemic sclerosis and lupus: points in an interferon-mediated continuum. Arthritis Rheum 2010, 62:589-598.
41. Gregersen P.K., Olsson L.M. Recent advances in the genetics of autoimmune disease. Annu Rev Immunol 2009, 27:363-391.
42. Kim D., Peck A., Santer D., Patole P., Schwartz S.M., Molitor J.A., et al. Induction of interferon-alpha by scleroderma sera containing autoantibodies to topoisomerase I: association of higher interferon-alpha activity with lung fibrosis. Arthritis Rheum 2008, 58:2163-2173.
43. Kalia S., Dutz J.P. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007, 20:160-174.
44. Perera G.K., Di Meglio P., Nestle F.O. Psoriasis. Annu Rev Pathol 2012, 7:385-422.
45. Jordan C.T., Cao L., Roberson E.D., Duan S., Helms C.A., Nair R.P., et al. Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasis. Am J Hum Genet 2012, 90:796-808.
46. Fuchs-Telem D., Sarig O., van Steensel M.A., Isakov O., Israeli S., Nousbeck J., et al. Familial pityriasis rubra pilaris is caused by mutations in CARD14. Am J Hum Genet 2012, 91:163-170.
47. Pasparakis M., Haase I., Nestle F.O. Mechanisms regulating skin immunity and inflammation. Nat Rev Immunol 2014, 14:289-301.
48. Kabashima K. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity. J Dermatol Sci 2013, 70:3-11.
49. Palmer C.N., Irvine A.D., Terron-Kwiatkowski A., Zhao Y., Liao H., Lee S.P., et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006, 38:441-446.
50. Nomura T., Sandilands A., Akiyama M., Liao H., Evans A.T., Sakai K., et al. Unique mutations in the filaggrin gene in Japanese patients with ichthyosis vulgaris and atopic dermatitis. J Allergy Clin Immunol 2007, 119:434-440.
51. Palmer C.N., Ismail T., Lee S.P., Terron-Kwiatkowski A., Zhao Y., Liao H., et al. Filaggrin null mutations are associated with increased asthma severity in children and young adults. J Allergy Clin Immunol 2007, 120:64-68.
52. Oji V., Eckl K.M., Aufenvenne K., Natebus M., Tarinski T., Ackermann K., et al. Loss of corneodesmosin leads to severe skin barrier defect, pruritus, and atopy: unraveling the peeling skin disease. Am J Hum Genet 2010, 87:274-281.
53. Samuelov L., Sarig O., Harmon R.M., Rapaport D., Ishida-Yamamoto A., Isakov O., et al. Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nat Genet 2013, 45:1244-1248.
54. Hadj-Rabia S., Baala L., Vabres P., Hamel-Teillac D., Jacquemin E., Fabre M., et al. Claudin-1 gene mutations in neonatal sclerosing cholangitis associated with ichthyosis: a tight junction disease. Gastroenterology 2004, 127:1386-1390.
55. De Benedetto A., Rafaels N.M., McGirt L.Y., Ivanov A.I., Georas S.N., Cheadle C., et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Immunol 2011, 127. 773-786 e771-777.
56. Grice E.A., Segre J.A. The skin microbiome. Nat Rev Microbiol 2011, 9:244-253.
57. Aly R., Shirley C., Cunico B., Maibach H.I. Effect of prolonged occlusion on the microbial flora, pH, carbon dioxide and transepidermal water loss on human skin. J Invest Dermatol 1978, 71:378-381.
58. Bickers D.R., Athar M. Oxidative stress in the pathogenesis of skin disease. J Invest Dermatol 2006, 126:2565-2575.
59. Kabashima K., Miyachi Y. Prostanoids in the cutaneous immune response. J Dermatol Sci 2004, 34:177-184.
60. Niyonsaba F., Ogawa H. Protective roles of the skin against infection: implication of naturally occurring human antimicrobial agents beta-defensins, cathelicidin LL-37 and lysozyme. J Dermatol Sci 2005, 40:157-168.
61. Nakatsuji T., Gallo R.L. Antimicrobial peptides: old molecules with new ideas. J Invest Dermatol 2012, 132:887-895.
62. Meyer-Hoffert U. Reddish, scaly, and itchy: how proteases and their inhibitors contribute to inflammatory skin diseases. Arch Immunol Ther Exp (Warsz) 2009, 57:345-354.
63. de Veer S.J., Furio L., Harris J.M., Hovnanian A. Proteases: common culprits in human skin disorders. Trends Mol Med 2014, 20:166-178.
64. Zaiou M., Nizet V., Gallo R.L. Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J Invest Dermatol 2003, 120:810-816.
65. Paul W.E., Zhu J. How are T(H)2-type immune responses initiated and amplified?. Nat Rev Immunol 2010, 10:225-235.
66. Sajid M., McKerrow J.H. Cysteine proteases of parasitic organisms. Mol Biochem Parasitol 2002, 120:1-21.
67. Novey H.S., Marchioli L.E., Sokol W.N., Wells I.D. Papain-induced asthma - physiological and immunological features. J Allergy Clin Immunol 1979, 63:98-103.
68. Halim T.Y., Krauss R.H., Sun A.C., Takei F. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 2012, 36:451-463.
69. Al-Ghouleh A., Johal R., Sharquie I.K., Emara M., Harrington H., Shakib F., et al. The glycosylation pattern of common allergens: the recognition and uptake of Der p 1 by epithelial and dendritic cells is carbohydrate dependent. PLoS ONE 2012, 7:e33929.
70. Motomura Y., Morita H., Moro K., Nakae S., Artis D., Endo T.A., et al. Basophil-derived interleukin-4 controls the function of natural helper cells, a member of ILC2s, in lung inflammation. Immunity 2014, 40:758-771.
71. Sokol C.L., Barton G.M., Farr A.G., Medzhitov R. A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Immunol 2008, 9:310-318.
72. Ohnmacht C., Schwartz C., Panzer M., Schiedewitz I., Naumann R., Voehringer D. Basophils orchestrate chronic allergic dermatitis and protective immunity against helminths. Immunity 2010, 33:364-374.
73. Tang H., Cao W., Kasturi S.P., Ravindran R., Nakaya H.I., Kundu K., et al. The T helper type 2 response to cysteine proteases requires dendritic cell-basophil cooperation via ROS-mediated signaling. Nat Immunol 2010, 11:608-617.
74. Taylor R.C., Cullen S.P., Martin S.J. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 2008, 9:231-241.
75. Lamkanfi M., Dixit V.M. Mechanisms and functions of inflammasomes. Cell 2014, 157:1013-1022.
76. Cayrol C., Girard J.P. The IL-1-like cytokine IL-33 is inactivated after maturation by caspase-1. Proc Natl Acad Sci U S A 2009, 106:9021-9026.
77. Park B., Brinkmann M.M., Spooner E., Lee C.C., Kim Y.M., Ploegh H.L. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat Immunol 2008, 9:1407-1414.
78. Pulendran B., Artis D. New paradigms in type 2 immunity. Science 2012, 337:431-435.
79. Honda T., Tokura Y., Miyachi Y., Kabashima K. Prostanoid receptors as possible targets for anti-allergic drugs: recent advances in prostanoids on allergy and immunology. Curr Drug Targets 2010, 11:1605-1613.
80. Nakahigashi K., Doi H., Otsuka A., Hirabayashi T., Murakami M., Urade Y., et al. PGD2 induces eotaxin-3 via PPARgamma from sebocytes: a possible pathogenesis of eosinophilic pustular folliculitis. J Allergy Clin Immunol 2012, 129:536-543.
81. Lazarczyk M., Cassonnet P., Pons C., Jacob Y., Favre M. The EVER proteins as a natural barrier against papillomaviruses: a new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009, 73:348-370.